Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edema
08/01/2019
When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point.
DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good vision, and non–CI-DME. Out of these, the prospective data are only substantial and persuasive when it comes to supporting pharmacologic intravitreal treatment of CI-DME with VA impairment with either medications that inhibit vascular endothelial growth factor (VEGF)-A[2,3] or corticosteroids.